Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study | BMC Cancer | Full Text

Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study | BMC Cancer | Full Text

Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study

The development and rapid uptake of immune checkpoint inhibitors (CPI) has changed the outlook for patients with cancer. However, CPIs have different adverse event (AE) profiles to other systemic therapies, an...

Authors:Liz Jamieson, Martin D. Forster, Kam Zaki, Sanjena Mithra, Heena Alli, Anne O’Connor, Apini Patel, Ian C. K. Wong and Pinkie Chambers

Citation:BMC Cancer 2020 20:743

Content type:Research article

 

Published on: 10 August 2020

• ViewFull Text
 
• ViewPDF